Literature DB >> 21700206

In situ kinase profiling reveals functionally relevant properties of native kinases.

Matthew P Patricelli1, Tyzoon K Nomanbhoy, Jiangyue Wu, Heidi Brown, David Zhou, Jianming Zhang, Subadhra Jagannathan, Arwin Aban, Eric Okerberg, Chris Herring, Brian Nordin, Helge Weissig, Qingkai Yang, Jiing-Dwan Lee, Nathanael S Gray, John W Kozarich.   

Abstract

Protein kinases are intensely studied mediators of cellular signaling, yet important questions remain regarding their regulation and in vivo properties. Here, we use a probe-based chemoprotemics platform to profile several well studied kinase inhibitors against >200 kinases in native cell proteomes and reveal biological targets for some of these inhibitors. Several striking differences were identified between native and recombinant kinase inhibitory profiles, in particular, for the Raf kinases. The native kinase binding profiles presented here closely mirror the cellular activity of these inhibitors, even when the inhibition profiles differ dramatically from recombinant assay results. Additionally, Raf activation events could be detected on live cell treatment with inhibitors. These studies highlight the complexities of protein kinase behavior in the cellular context and demonstrate that profiling with only recombinant/purified enzymes can be misleading.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21700206      PMCID: PMC3142620          DOI: 10.1016/j.chembiol.2011.04.011

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  42 in total

Review 1.  The structure-based design of ATP-site directed protein kinase inhibitors.

Authors:  L M Toledo; N B Lydon; D Elbaum
Journal:  Curr Med Chem       Date:  1999-09       Impact factor: 4.530

Review 2.  The protein kinase complement of the human genome.

Authors:  G Manning; D B Whyte; R Martinez; T Hunter; S Sudarsanam
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

3.  An efficient proteomics method to identify the cellular targets of protein kinase inhibitors.

Authors:  Klaus Godl; Josef Wissing; Alexander Kurtenbach; Peter Habenberger; Stephanie Blencke; Heidrun Gutbrod; Kostadinos Salassidis; Matthias Stein-Gerlach; Andrea Missio; Matt Cotten; Henrik Daub
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-10       Impact factor: 11.205

Review 4.  Protein kinases--the major drug targets of the twenty-first century?

Authors:  Philip Cohen
Journal:  Nat Rev Drug Discov       Date:  2002-04       Impact factor: 84.694

Review 5.  Features of selective kinase inhibitors.

Authors:  Zachary A Knight; Kevan M Shokat
Journal:  Chem Biol       Date:  2005-06

6.  Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.

Authors:  Martin H Cohen; Grant Williams; John R Johnson; John Duan; Jogarao Gobburu; Atiqur Rahman; Kimberly Benson; John Leighton; Sung K Kim; Rebecca Wood; Mark Rothmann; Gang Chen; Khin Maung U; Ann M Staten; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2002-05       Impact factor: 12.531

7.  Discovering potent and selective reversible inhibitors of enzymes in complex proteomes.

Authors:  Donmienne Leung; Christophe Hardouin; Dale L Boger; Benjamin F Cravatt
Journal:  Nat Biotechnol       Date:  2003-05-12       Impact factor: 54.908

8.  BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo.

Authors:  Yvonne Kuma; Guadalupe Sabio; Jenny Bain; Natalia Shpiro; Rodolfo Márquez; Ana Cuenda
Journal:  J Biol Chem       Date:  2005-03-08       Impact factor: 5.157

9.  Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site.

Authors:  Christopher Pargellis; Liang Tong; Laurie Churchill; Pier F Cirillo; Thomas Gilmore; Anne G Graham; Peter M Grob; Eugene R Hickey; Neil Moss; Susan Pav; John Regan
Journal:  Nat Struct Biol       Date:  2002-04

10.  The kinetics of binding to p38MAP kinase by analogues of BIRB 796.

Authors:  John Regan; Christopher A Pargellis; Pier F Cirillo; Thomas Gilmore; Eugene R Hickey; Gregory W Peet; Alfred Proto; Alan Swinamer; Neil Moss
Journal:  Bioorg Med Chem Lett       Date:  2003-09-15       Impact factor: 2.823

View more
  136 in total

1.  A Chemoproteomic Strategy for Direct and Proteome-Wide Covalent Inhibitor Target-Site Identification.

Authors:  Christopher M Browne; Baishan Jiang; Scott B Ficarro; Zainab M Doctor; Jared L Johnson; Joseph D Card; Sindhu Carmen Sivakumaren; William M Alexander; Tomer M Yaron; Charles J Murphy; Nicholas P Kwiatkowski; Tinghu Zhang; Lewis C Cantley; Nathanael S Gray; Jarrod A Marto
Journal:  J Am Chem Soc       Date:  2018-12-20       Impact factor: 15.419

Review 2.  Targeting protein kinases with selective and semipromiscuous covalent inhibitors.

Authors:  Rand M Miller; Jack Taunton
Journal:  Methods Enzymol       Date:  2014       Impact factor: 1.600

3.  Interrogating the kinome.

Authors:  Chao Zhang; Gaston Habets; Gideon Bollag
Journal:  Nat Biotechnol       Date:  2011-11-08       Impact factor: 54.908

4.  Discovery of an in Vivo Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment.

Authors:  Mark Ammirati; Scott W Bagley; Samit K Bhattacharya; Leonard Buckbinder; Anthony A Carlo; Rebecca Conrad; Christian Cortes; Robert L Dow; Matthew S Dowling; Ayman El-Kattan; Kristen Ford; Cristiano R W Guimarães; David Hepworth; Wenhua Jiao; Jennifer LaPerle; Shenping Liu; Allyn Londregan; Paula M Loria; Alan M Mathiowetz; Michael Munchhof; Suvi T M Orr; Donna N Petersen; David A Price; Athanasia Skoura; Aaron C Smith; Jian Wang
Journal:  ACS Med Chem Lett       Date:  2015-10-06       Impact factor: 4.345

5.  Liganding Functional Tyrosine Sites on Proteins Using Sulfur-Triazole Exchange Chemistry.

Authors:  Jeffrey W Brulet; Adam L Borne; Kun Yuan; Adam H Libby; Ku-Lung Hsu
Journal:  J Am Chem Soc       Date:  2020-04-24       Impact factor: 15.419

6.  How chemoproteomics can enable drug discovery and development.

Authors:  Raymond E Moellering; Benjamin F Cravatt
Journal:  Chem Biol       Date:  2012-01-27

7.  Discovery of Covalent CDK14 Inhibitors with Pan-TAIRE Family Specificity.

Authors:  Fleur M Ferguson; Zainab M Doctor; Scott B Ficarro; Christopher M Browne; Jarrod A Marto; Jared L Johnson; Tomer M Yaron; Lewis C Cantley; Nam Doo Kim; Taebo Sim; Matthew J Berberich; Marian Kalocsay; Peter K Sorger; Nathanael S Gray
Journal:  Cell Chem Biol       Date:  2019-03-28       Impact factor: 8.116

8.  The Ligand Binding Landscape of Diacylglycerol Kinases.

Authors:  Caroline E Franks; Sean T Campbell; Benjamin W Purow; Thurl E Harris; Ku-Lung Hsu
Journal:  Cell Chem Biol       Date:  2017-07-14       Impact factor: 8.116

9.  Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.

Authors:  Tinghu Zhang; Nicholas Kwiatkowski; Calla M Olson; Sarah E Dixon-Clarke; Brian J Abraham; Ann K Greifenberg; Scott B Ficarro; Jonathan M Elkins; Yanke Liang; Nancy M Hannett; Theresa Manz; Mingfeng Hao; Bartlomiej Bartkowiak; Arno L Greenleaf; Jarrod A Marto; Matthias Geyer; Alex N Bullock; Richard A Young; Nathanael S Gray
Journal:  Nat Chem Biol       Date:  2016-08-29       Impact factor: 15.040

10.  A quantitative proteomics-based competition binding assay to characterize pITAM-protein interactions.

Authors:  Lianghai Hu; Li Yang; Andrew M Lipchik; Robert L Geahlen; Laurie L Parker; W Andy Tao
Journal:  Anal Chem       Date:  2013-05-08       Impact factor: 6.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.